A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Condition:   Colorectal Neoplasms
Interventions:   Drug: tucatinib;   Drug: trastuzumab;   Drug: bevacizumab;   Drug: cetuximab;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: levoleucovorin;   Drug: fluorouracil
Sponsors:   Seagen Inc.;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 5, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments